Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan

Keiichi Ito, Shuji Mikami, Katsunori Tatsugami, Naoya Masumori, Nobuo Shinohara, Tsunenori Kondo, Shotaro Nakanishi, Yoji Nagashima, Masatoshi Eto, Tomomi Kamba, Naoto Kuroda, Yoshihiko Tomita, Hideyasu Matsuyama, Tetsuro Onishi, Tomoyasu Tsushima, Hayakazu Nakazawa, Mototsugu Oya, Seiichiro Ozono, Seiji Naito, Tomohiko Asano

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Standard treatments have not been established in metastatic papillary renal-cell carcinoma (PRCC). We aimed to investigate treatment outcomes in patients with mPRCC. Patients and Methods: This study included 51 patients who were diagnosed with PRCC at 14 institutions. Pathologic slides were reviewed by pathologists. The associations between clinical factors and overall survival (OS) were analyzed. Results: Final pathologic diagnoses could be determined in 50 patients. Thirty-five tumors were diagnosed as PRCC (type 2 PRCC, 91.4%), and 15 were diagnosed as other histologic types. Targeted therapies (TTs) were provided to 25 mPRCC patients. Patients treated with TT survived significantly longer than those treated before the era of TT (median OS, 22.5 vs. 6.3 months; P = .0035). Median OS of patients who experienced stable disease for ≥ 9 months using single TT was 43.1 months. Patients treated with a tyrosine kinase inhibitor (TKI) as first-line TT survived longer after TT initiation than those treated with an mTOR inhibitor (median, 22.4 vs. 11.7 months; P = .2684). Patients treated with TKIs in both first- and second-line settings had significantly better survival after TT initiation than those treated with a TKI in one therapy line and an mTOR inhibitor in the other (31.4 vs. 12.9 months, P = .0172). Patients treated with a TKI as second-line TT survived significantly longer after second-line TT initiation than did those treated with an mTOR inhibitor (16.2 vs. 7.4 months, P = .0016). Conclusion: Prognoses of patients with mPRCC were improved by TT, and TKIs appeared to be the treatment of choice in both the first- and second-line settings. We aimed to investigate treatment outcomes in patients with metastatic papillary renal-cell carcinoma. Patients treated with targeted therapy (TT) survived significantly longer than those treated before the era of TT. Patients treated with tyrosine kinase inhibitors (TKIs) in both first- and second-line settings had significantly better survival after initiation of TT than those treated with a TKI in one therapy line and an mTOR inhibitor in the other.

Original languageEnglish
Pages (from-to)e1201-e1214
JournalClinical Genitourinary Cancer
Volume16
Issue number6
DOIs
Publication statusPublished - Dec 1 2018

Fingerprint

Renal Cell Carcinoma
Japan
Protein-Tyrosine Kinases
Therapeutics
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Urology

Cite this

Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma : A Multi-Institutional Study in Japan. / Ito, Keiichi; Mikami, Shuji; Tatsugami, Katsunori; Masumori, Naoya; Shinohara, Nobuo; Kondo, Tsunenori; Nakanishi, Shotaro; Nagashima, Yoji; Eto, Masatoshi; Kamba, Tomomi; Kuroda, Naoto; Tomita, Yoshihiko; Matsuyama, Hideyasu; Onishi, Tetsuro; Tsushima, Tomoyasu; Nakazawa, Hayakazu; Oya, Mototsugu; Ozono, Seiichiro; Naito, Seiji; Asano, Tomohiko.

In: Clinical Genitourinary Cancer, Vol. 16, No. 6, 01.12.2018, p. e1201-e1214.

Research output: Contribution to journalArticle

Ito, K, Mikami, S, Tatsugami, K, Masumori, N, Shinohara, N, Kondo, T, Nakanishi, S, Nagashima, Y, Eto, M, Kamba, T, Kuroda, N, Tomita, Y, Matsuyama, H, Onishi, T, Tsushima, T, Nakazawa, H, Oya, M, Ozono, S, Naito, S & Asano, T 2018, 'Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan', Clinical Genitourinary Cancer, vol. 16, no. 6, pp. e1201-e1214. https://doi.org/10.1016/j.clgc.2018.07.028
Ito, Keiichi ; Mikami, Shuji ; Tatsugami, Katsunori ; Masumori, Naoya ; Shinohara, Nobuo ; Kondo, Tsunenori ; Nakanishi, Shotaro ; Nagashima, Yoji ; Eto, Masatoshi ; Kamba, Tomomi ; Kuroda, Naoto ; Tomita, Yoshihiko ; Matsuyama, Hideyasu ; Onishi, Tetsuro ; Tsushima, Tomoyasu ; Nakazawa, Hayakazu ; Oya, Mototsugu ; Ozono, Seiichiro ; Naito, Seiji ; Asano, Tomohiko. / Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma : A Multi-Institutional Study in Japan. In: Clinical Genitourinary Cancer. 2018 ; Vol. 16, No. 6. pp. e1201-e1214.
@article{055c5bc035084edcb9fa3f4c0b79d13d,
title = "Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan",
abstract = "Background: Standard treatments have not been established in metastatic papillary renal-cell carcinoma (PRCC). We aimed to investigate treatment outcomes in patients with mPRCC. Patients and Methods: This study included 51 patients who were diagnosed with PRCC at 14 institutions. Pathologic slides were reviewed by pathologists. The associations between clinical factors and overall survival (OS) were analyzed. Results: Final pathologic diagnoses could be determined in 50 patients. Thirty-five tumors were diagnosed as PRCC (type 2 PRCC, 91.4{\%}), and 15 were diagnosed as other histologic types. Targeted therapies (TTs) were provided to 25 mPRCC patients. Patients treated with TT survived significantly longer than those treated before the era of TT (median OS, 22.5 vs. 6.3 months; P = .0035). Median OS of patients who experienced stable disease for ≥ 9 months using single TT was 43.1 months. Patients treated with a tyrosine kinase inhibitor (TKI) as first-line TT survived longer after TT initiation than those treated with an mTOR inhibitor (median, 22.4 vs. 11.7 months; P = .2684). Patients treated with TKIs in both first- and second-line settings had significantly better survival after TT initiation than those treated with a TKI in one therapy line and an mTOR inhibitor in the other (31.4 vs. 12.9 months, P = .0172). Patients treated with a TKI as second-line TT survived significantly longer after second-line TT initiation than did those treated with an mTOR inhibitor (16.2 vs. 7.4 months, P = .0016). Conclusion: Prognoses of patients with mPRCC were improved by TT, and TKIs appeared to be the treatment of choice in both the first- and second-line settings. We aimed to investigate treatment outcomes in patients with metastatic papillary renal-cell carcinoma. Patients treated with targeted therapy (TT) survived significantly longer than those treated before the era of TT. Patients treated with tyrosine kinase inhibitors (TKIs) in both first- and second-line settings had significantly better survival after initiation of TT than those treated with a TKI in one therapy line and an mTOR inhibitor in the other.",
author = "Keiichi Ito and Shuji Mikami and Katsunori Tatsugami and Naoya Masumori and Nobuo Shinohara and Tsunenori Kondo and Shotaro Nakanishi and Yoji Nagashima and Masatoshi Eto and Tomomi Kamba and Naoto Kuroda and Yoshihiko Tomita and Hideyasu Matsuyama and Tetsuro Onishi and Tomoyasu Tsushima and Hayakazu Nakazawa and Mototsugu Oya and Seiichiro Ozono and Seiji Naito and Tomohiko Asano",
year = "2018",
month = "12",
day = "1",
doi = "10.1016/j.clgc.2018.07.028",
language = "English",
volume = "16",
pages = "e1201--e1214",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma

T2 - A Multi-Institutional Study in Japan

AU - Ito, Keiichi

AU - Mikami, Shuji

AU - Tatsugami, Katsunori

AU - Masumori, Naoya

AU - Shinohara, Nobuo

AU - Kondo, Tsunenori

AU - Nakanishi, Shotaro

AU - Nagashima, Yoji

AU - Eto, Masatoshi

AU - Kamba, Tomomi

AU - Kuroda, Naoto

AU - Tomita, Yoshihiko

AU - Matsuyama, Hideyasu

AU - Onishi, Tetsuro

AU - Tsushima, Tomoyasu

AU - Nakazawa, Hayakazu

AU - Oya, Mototsugu

AU - Ozono, Seiichiro

AU - Naito, Seiji

AU - Asano, Tomohiko

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Background: Standard treatments have not been established in metastatic papillary renal-cell carcinoma (PRCC). We aimed to investigate treatment outcomes in patients with mPRCC. Patients and Methods: This study included 51 patients who were diagnosed with PRCC at 14 institutions. Pathologic slides were reviewed by pathologists. The associations between clinical factors and overall survival (OS) were analyzed. Results: Final pathologic diagnoses could be determined in 50 patients. Thirty-five tumors were diagnosed as PRCC (type 2 PRCC, 91.4%), and 15 were diagnosed as other histologic types. Targeted therapies (TTs) were provided to 25 mPRCC patients. Patients treated with TT survived significantly longer than those treated before the era of TT (median OS, 22.5 vs. 6.3 months; P = .0035). Median OS of patients who experienced stable disease for ≥ 9 months using single TT was 43.1 months. Patients treated with a tyrosine kinase inhibitor (TKI) as first-line TT survived longer after TT initiation than those treated with an mTOR inhibitor (median, 22.4 vs. 11.7 months; P = .2684). Patients treated with TKIs in both first- and second-line settings had significantly better survival after TT initiation than those treated with a TKI in one therapy line and an mTOR inhibitor in the other (31.4 vs. 12.9 months, P = .0172). Patients treated with a TKI as second-line TT survived significantly longer after second-line TT initiation than did those treated with an mTOR inhibitor (16.2 vs. 7.4 months, P = .0016). Conclusion: Prognoses of patients with mPRCC were improved by TT, and TKIs appeared to be the treatment of choice in both the first- and second-line settings. We aimed to investigate treatment outcomes in patients with metastatic papillary renal-cell carcinoma. Patients treated with targeted therapy (TT) survived significantly longer than those treated before the era of TT. Patients treated with tyrosine kinase inhibitors (TKIs) in both first- and second-line settings had significantly better survival after initiation of TT than those treated with a TKI in one therapy line and an mTOR inhibitor in the other.

AB - Background: Standard treatments have not been established in metastatic papillary renal-cell carcinoma (PRCC). We aimed to investigate treatment outcomes in patients with mPRCC. Patients and Methods: This study included 51 patients who were diagnosed with PRCC at 14 institutions. Pathologic slides were reviewed by pathologists. The associations between clinical factors and overall survival (OS) were analyzed. Results: Final pathologic diagnoses could be determined in 50 patients. Thirty-five tumors were diagnosed as PRCC (type 2 PRCC, 91.4%), and 15 were diagnosed as other histologic types. Targeted therapies (TTs) were provided to 25 mPRCC patients. Patients treated with TT survived significantly longer than those treated before the era of TT (median OS, 22.5 vs. 6.3 months; P = .0035). Median OS of patients who experienced stable disease for ≥ 9 months using single TT was 43.1 months. Patients treated with a tyrosine kinase inhibitor (TKI) as first-line TT survived longer after TT initiation than those treated with an mTOR inhibitor (median, 22.4 vs. 11.7 months; P = .2684). Patients treated with TKIs in both first- and second-line settings had significantly better survival after TT initiation than those treated with a TKI in one therapy line and an mTOR inhibitor in the other (31.4 vs. 12.9 months, P = .0172). Patients treated with a TKI as second-line TT survived significantly longer after second-line TT initiation than did those treated with an mTOR inhibitor (16.2 vs. 7.4 months, P = .0016). Conclusion: Prognoses of patients with mPRCC were improved by TT, and TKIs appeared to be the treatment of choice in both the first- and second-line settings. We aimed to investigate treatment outcomes in patients with metastatic papillary renal-cell carcinoma. Patients treated with targeted therapy (TT) survived significantly longer than those treated before the era of TT. Patients treated with tyrosine kinase inhibitors (TKIs) in both first- and second-line settings had significantly better survival after initiation of TT than those treated with a TKI in one therapy line and an mTOR inhibitor in the other.

UR - http://www.scopus.com/inward/record.url?scp=85053222708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053222708&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2018.07.028

DO - 10.1016/j.clgc.2018.07.028

M3 - Article

C2 - 30224330

AN - SCOPUS:85053222708

VL - 16

SP - e1201-e1214

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 6

ER -